Lallemand Health Solutions and dsm-firmenich are joining forces to launch early-life synbiotic solutions, leveraging the synergy of probiotics and human milk oligosaccharides (HMOs). Unlocking the synergy between probiotics and HMOs to provide infants with the […]
Leveraging gamers and video game technology can dramatically boost scientific research according to a new study published on April 15th in Nature Biotechnology. 4.5 million gamers around the world have advanced medical science by helping […]
SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, announces today that it has received $5.48 million from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (“CARB-X”) to […]
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis. […]
Researchers at the University of Chicago have developed a new generative artificial intelligence (AI) tool that models the infant microbiome. This “digital twin” of the infant microbiome creates a virtual model that predicts the changing […]
With resistance to chemical antibiotics on the rise, the world needs entirely new forms of antibiotics. A new study published in Microbiology Spectrum, a journal of the American Society for Microbiology, shows that an enzymatic cocktail […]
BioMe, a prominent player in the field of Live Biotherapeutic Products (LBPs), has recently made significant strides with its latest drug development candidate, BM109, aimed at treating Cardiovascular Disease (CVD) and Chronic Kidney Disease (CKD) […]
Nestlé’s recently launched Petivity Microbiome Analysis Kit in the U.S. helps to deliver tailored nutrition and supplement recommendations for dogs and cats based on their unique gut profile. Through science-based sequencing technology of a pet’s microbiome, the new analysis […]
EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the Company has completed its £27m ($34m USD) funding round, supported by new and existing investors. The funding will […]